Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CHARLOTTE C SUN and KAREN H LU.
CHARLOTTE C SUN
Connection Strength
4.121
KAREN H LU
  1. Women's preferences for cancer risk management strategies in Lynch syndrome. Gynecol Oncol. 2019 03; 152(3):514-521.
    View in: PubMed
    Score: 0.167
  2. Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic. Gynecol Oncol. 2019 02; 152(2):328-333.
    View in: PubMed
    Score: 0.165
  3. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations. Gynecol Oncol. 2018 07; 150(1):79-84.
    View in: PubMed
    Score: 0.158
  4. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Gynecol Oncol. 2017 08; 146(2):399-404.
    View in: PubMed
    Score: 0.148
  5. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol. 2017 08; 146(2):234-239.
    View in: PubMed
    Score: 0.148
  6. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol. 2017 Apr 01; 35(10):1103-1111.
    View in: PubMed
    Score: 0.145
  7. Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN. Oncology. 2017; 92(2):109-114.
    View in: PubMed
    Score: 0.143
  8. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin Oncol. 2015 Aug 20; 33(24):2675-82.
    View in: PubMed
    Score: 0.130
  9. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol. 2014 May; 133(2):283-6.
    View in: PubMed
    Score: 0.118
  10. Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. Am J Obstet Gynecol. 2014 Mar; 210(3):257.e1-6.
    View in: PubMed
    Score: 0.116
  11. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013 Oct 01; 119(19):3454-61.
    View in: PubMed
    Score: 0.114
  12. Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome. Cancer. 2013 Aug 15; 119(16):3027-33.
    View in: PubMed
    Score: 0.113
  13. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol. 2011 Jun 01; 29(16):2247-52.
    View in: PubMed
    Score: 0.097
  14. Prospective study of combined colon and endometrial cancer screening in women with lynch syndrome: a patient-centered approach. J Oncol Pract. 2011 Jan; 7(1):43-7.
    View in: PubMed
    Score: 0.095
  15. Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer? Gynecol Oncol. 2011 Feb; 120(2):229-32.
    View in: PubMed
    Score: 0.094
  16. Obstetrics/gynecology residents' knowledge of hereditary breast and ovarian cancer and Lynch syndrome. J Cancer Educ. 2010 Sep; 25(3):401-4.
    View in: PubMed
    Score: 0.093
  17. Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes. Fam Cancer. 2010 Sep; 9(3):479-87.
    View in: PubMed
    Score: 0.093
  18. Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J Clin Oncol. 2010 Feb 01; 28(4):675-82.
    View in: PubMed
    Score: 0.087
  19. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer. 2008 Jul 15; 113(2):326-35.
    View in: PubMed
    Score: 0.080
  20. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol. 2007 Nov 20; 25(33):5158-64.
    View in: PubMed
    Score: 0.076
  21. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol. 2006 Sep; 108(3 Pt 1):515-20.
    View in: PubMed
    Score: 0.070
  22. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006 Jan 19; 354(3):261-9.
    View in: PubMed
    Score: 0.067
  23. Endometrial cancer in young, normal-weight women. Gynecol Oncol. 2005 Nov; 99(2):388-92.
    View in: PubMed
    Score: 0.065
  24. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005 Mar; 105(3):569-74.
    View in: PubMed
    Score: 0.063
  25. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005 Mar; 105(3):575-80.
    View in: PubMed
    Score: 0.063
  26. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004 Aug 01; 22(15):3126-32.
    View in: PubMed
    Score: 0.061
  27. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol. 2004 Aug; 104(2):255-60.
    View in: PubMed
    Score: 0.061
  28. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol. 2004 Aug; 94(2):456-62.
    View in: PubMed
    Score: 0.061
  29. Determination of quality of life-related health utilities for surgical complications in ovarian cancer. Gynecol Oncol. 2024 06; 185:101-107.
    View in: PubMed
    Score: 0.059
  30. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2024 04 01; 130(7):1061-1071.
    View in: PubMed
    Score: 0.058
  31. Predicting 180-day mortality for women with ovarian cancer using machine learning and patient-reported outcome data. Sci Rep. 2022 12 08; 12(1):21269.
    View in: PubMed
    Score: 0.054
  32. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
    View in: PubMed
    Score: 0.050
  33. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. Am J Obstet Gynecol. 2021 07; 225(1):68.e1-68.e11.
    View in: PubMed
    Score: 0.048
  34. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2021 04; 161(1):56-62.
    View in: PubMed
    Score: 0.048
  35. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
    View in: PubMed
    Score: 0.046
  36. National trends in bowel and upper abdominal procedures in ovarian cancer surgery. Int J Gynecol Cancer. 2020 08; 30(8):1195-1202.
    View in: PubMed
    Score: 0.046
  37. Body mass index and attitudes towards health behaviors among women with endometrial cancer before and after treatment. Int J Gynecol Cancer. 2020 02; 30(2):187-192.
    View in: PubMed
    Score: 0.044
  38. Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes. Gynecol Oncol. 2019 08; 154(2):405-410.
    View in: PubMed
    Score: 0.043
  39. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Am J Obstet Gynecol. 2019 08; 221(2):136.e1-136.e9.
    View in: PubMed
    Score: 0.042
  40. National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer. Gynecol Oncol. 2019 03; 152(3):439-444.
    View in: PubMed
    Score: 0.042
  41. Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. Gynecol Oncol. 2019 03; 152(3):501-508.
    View in: PubMed
    Score: 0.042
  42. Disparities in treatment and survival among elderly ovarian cancer patients. Gynecol Oncol. 2018 11; 151(2):269-274.
    View in: PubMed
    Score: 0.041
  43. Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstet Gynecol. 2018 07; 132(1):52-58.
    View in: PubMed
    Score: 0.040
  44. Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecol Oncol. 2018 09; 150(3):451-459.
    View in: PubMed
    Score: 0.040
  45. Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer. Int J Gynecol Cancer. 2018 02; 28(2):285-292.
    View in: PubMed
    Score: 0.039
  46. Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. Int J Gynecol Cancer. 2017 09; 27(7):1350-1359.
    View in: PubMed
    Score: 0.038
  47. Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecol Oncol. 2017 04; 145(1):55-60.
    View in: PubMed
    Score: 0.036
  48. Endometrial Cancer Associated Symptoms: A Case-Control Study. J Womens Health (Larchmt). 2016 11; 25(11):1187-1192.
    View in: PubMed
    Score: 0.035
  49. Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv. 2016 Apr; 10(2):261-70.
    View in: PubMed
    Score: 0.033
  50. Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer. Cancer Prev Res (Phila). 2014 Jul; 7(7):686-97.
    View in: PubMed
    Score: 0.030
  51. Gynecologic cancer screening and communication with health care providers in women with Lynch syndrome. Clin Genet. 2014 Aug; 86(2):185-9.
    View in: PubMed
    Score: 0.029
  52. Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center. Fam Cancer. 2011 Dec; 10(4):673-9.
    View in: PubMed
    Score: 0.025
  53. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94.
    View in: PubMed
    Score: 0.025
  54. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer. 2011 Jun 15; 117(12):2659-67.
    View in: PubMed
    Score: 0.024
  55. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol. 2010 Oct; 177(4):1611-7.
    View in: PubMed
    Score: 0.023
  56. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010 Sep 20; 28(27):4214-20.
    View in: PubMed
    Score: 0.023
  57. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer. 2009 Apr 15; 115(8):1598-604.
    View in: PubMed
    Score: 0.021
  58. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009 Jul; 114(1):48-52.
    View in: PubMed
    Score: 0.021
  59. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol. 2007 Jun; 105(3):625-9.
    View in: PubMed
    Score: 0.018
  60. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther. 2006 Sep; 5(9):1136-41.
    View in: PubMed
    Score: 0.018
  61. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006 Aug; 108(2):361-8.
    View in: PubMed
    Score: 0.017
  62. Are women ready for the HPV vaccine? Gynecol Oncol. 2006 Oct; 103(1):151-4.
    View in: PubMed
    Score: 0.017
  63. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer. 2003 Aug 15; 98(4):758-64.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.